Navigation Links
Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
Date:6/30/2011

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 – 7, 2011, in Amsterdam, The Netherlands.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-151MM-151 is designed to effectively block downstream signaling of the EGFR receptor, a key oncogene in various carcinomas. The poster will present pre-clinical data regarding the potency of MM-151 compared to existing monoclonal therapies targeting EGFR.Poster #3656 presents preclinical data on the ability of  MM-151 to effectively block EGFR pathway activation in in-vitro signaling and inhibit tumor cell growth in-vitro and in-vivo in lung cancer modelsPoster Session:  P2.070: Poster Session 2

Number:  3656

Date/Time:  Tuesday, July 5, from 12:15 PM – 2:00 PM

Location:  RAI Exhibition and Convention Centre, Exhibition HallMM-398  

MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors.  MM-398, in partnership with PharmaEngine, Inc., is in clinical development in colorectal, gastric and pancreatic cancer and in glioma.  The poster will present preclinical data on the safety and activity of MM-398 in lung cancer xenograft models.Poster #S420-421 presents preclinical data on MM-398's safety and activity Oral Session:  033.03: Preclinical Models 1

Number:  S420-421

Date/Time:  Wednesday, July 6, from 2:30 PM – 4:00 PM

Location:  Room D201About Merrimack Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer. Merrimack is advancing a pipeline of engineered therapeutics paired with molecular diagnostics. In addition to several pre-clinical and research-stage programs, Merrimack has five oncology candidates in clinical development or expected to enter clinical development this year: MM-398, in Phase 2 testing in partnership with PharmaEngine, Inc., MM-121, in Phase 2 testing in partnership with Sanofi, MM-111 in Phase 1 / 2 testing; and MM-302 and MM-151, which are both expected to enter Phase 1 clinical development this year. MM-398, MM-121, MM-111, MM-302 and MM-151 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Merrimack uses its proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, to integrate the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutic s and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact:  Rachel Yaroschuk, Corporate Communications, Merrimack, 617-441-7414  
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
2. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
3. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
4. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
6. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
7. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
8. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
9. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
11. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
Breaking Biology Technology:
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
Breaking Biology News(10 mins):